Search

Author/Creator Swayze, Eric

1. [O2–17–02]: DISCOVERY AND EARLY CLINICAL DEVELOPMENT OF IONIS‐MAPTRX, THE FIRST TAU‐LOWERING ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH MILD AD. (1st July 2017)

Authors:
Lane, Roger M.; Kordasiewicz, Holly B.; Smith, Anne; Mignon, Laurence; Miller, Timothy M.; Mummery, Catherine J.; Andreasen, Niels; Narayanan, Padma; Swayze, Eric; Norris, Daniel A.; Fitzsimmons, Bethany; Bennett, C Frank
Journal:
Alzheimer's & dementia
Issue:
Volume 13:Supplement 7S(2017)Part 12
Page Start:
P600
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. J01 Effects of IONIS-HTTRX (RG6042) in patients with early huntington's disease, results of the first htt-lowering drug trial. (September 2018)

Authors:
Tabrizi, Sarah J; Leavitt, Blair; Landwehrmeyer, Bernhard; Wild, Edward; Saft, Carsten; Barker, Roger; Craufurd, David; Rickards, Hugh; Rosser, Anne; Priller, Josef; Kordasiewicz, Holly; Czech, Christian; Swayze, Eric; Norris, Daniel A; Baumann, Tiffany; Gerlach, Irene; Schobel, Scott; Smith, Ann...
Journal:
Journal of neurology, neurosurgery and psychiatry
Issue:
Volume 89(2018)Supplement 1
Page Start:
A97
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses. Issue 10 (16th August 2022)

Authors:
Han, Kelong; Theodore, Dickens; McMullen, Gina; Swayze, Eric; McCaleb, Michael; Billioud, Gaetan; Wieland, Stefan; Hood, Steve; Paff, Melanie; Bennett, C. Frank; Kwoh, T. Jesse
Journal:
Clinical pharmacology in drug development
Issue:
Volume 11:Issue 10(2022)
Page Start:
1191
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Protein production is an early biomarker for RNA‐targeted therapies. Issue 12 (14th October 2018)

Authors:
Self, Wade K.; Schoch, Kathleen M.; Alex, Jacob; Barthélemy, Nicolas; Bollinger, James G.; Sato, Chihiro; Cole, Tracy; Kordasiewicz, Holly B.; Swayze, Eric; Bateman, Randall J.; Miller, Timothy M.
Journal:
Annals of clinical and translational neurology
Issue:
Volume 5:Issue 12(2018)
Page Start:
1492
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗